التفاصيل البيبلوغرافية
| العنوان: |
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. |
| المؤلفون: |
Zang, R Y, Harter, P, Chi, D S, Sehouli, J, Jiang, R, Tropé, C G, Ayhan, A, Cormio, G, Xing, Y, Wollschlaeger, K M, Braicu, E I, Rabbitt, C A, Oksefjell, H, Tian, W J, Fotopoulou, C, Pfisterer, J, du Bois, A, Berek, J S, Tropé, C G |
| المصدر: |
British Journal of Cancer; 9/27/2011, Vol. 105 Issue 7, p890-896, 7p, 3 Charts, 3 Graphs |
| مصطلحات موضوعية: |
OVARIAN cancer, CANCER patients, SURVIVAL behavior (Humans), ONCOLOGIC surgery, CANCER relapse, COHORT analysis |
| مستخلص: |
Background: This study aims to identify prognostic factors and to develop a risk model predicting survival in patients undergoing secondary cytoreductive surgery (SCR) for recurrent epithelial ovarian cancer.Methods: Individual data of 1100 patients with recurrent ovarian cancer of a progression-free interval at least 6 months who underwent SCR were pooled analysed. A simplified scoring system for each independent prognostic factor was developed according to its coefficient. Internal validation was performed to assess the discrimination of the model.Results: Complete SCR was strongly associated with the improvement of survival, with a median survival of 57.7 months, when compared with 27.0 months in those with residual disease of 0.1-1 cm and 15.6 months in those with residual disease of >1 cm, respectively (P<0.0001). Progression-free interval (≤23.1 months vs >23.1 months, hazard ratio (HR): 1.72; score: 2), ascites at recurrence (present vs absent, HR: 1.27; score: 1), extent of recurrence (multiple vs localised disease, HR: 1.38; score: 1) as well as residual disease after SCR (R1 vs R0, HR: 1.90, score: 2; R2 vs R0, HR: 3.0, score: 4) entered into the risk model.Conclusion: This prognostic model may provide evidence to predict survival benefit from secondary cytoreduction in patients with recurrent ovarian cancer. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder